Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
J. Michael Gaziano,Anthony H. Cincotta,Aaron I. Vinik,Lawrence Blonde,Nancy J. V. Bohannon,Richard E. Scranton +5 more
Reads0
Chats0
TLDR
The present investigation was undertaken to more critically evaluate the impact of bromocriptine-QR on cardiovascular outcomes in this study subject population by including CV death in the above-described original composite analysis and stratifying this new analysis on the basis of multiple demographic subgroups.Abstract:
Background-—Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug Administrration–approved treatment for type 2 diabetes mellitus (T2DM). A 3070-subject randomized trial demonstrated a significant, 40% reduction in relative risk among bromocriptine-QR-treated subjects in a prespecified composite cardiovascular (CV) end point that included ischemic-related (myocardial infarction and stroke) and nonischemic-related (hospitalization for unstable angina, congestive heart failure [CHF], or revascularization surgery) end points, but did not include cardiovascular death as a component of this composite. The present investigation was undertaken to more critically evaluate the impact of bromocriptine-QR on cardiovascular outcomes in this study subject population by (1) including CV death in the above-described original composite analysis and then stratifying this new analysis on the basis of multiple demographic subgroups and (2) analyzing the influence of this intervention on only the “hard” CV end points of myocardial infarction, stroke, and CV death (major adverse cardiovascular events [MACEs]). Methods and Results-—Three thousand seventy T2DM subjects on stable doses of ≤2 antidiabetes medications (including insulin) with HbA1c ≤10.0 (average baseline HbA1c=7.0) were randomized 2:1 to bromocriptine-QR (1.6 to 4.8 mg/day) or placebo for a 52-week treatment period. Subjects with heart failure (New York Heart Classes I and II) and precedent myocardial infarction or revascularization surgery were allowed to participate in the trial. Study outcomes included time to first event for each of the 2 CV composite end points described above. The relative risk comparing bromocriptine-QR with the control for the cardiovascular outcomes was estimated as a hazard ratio with 95% confidence interval on the basis of Cox proportional hazards regression. The statistical significance of any between-group difference in the cumulative percentage of CV events over time (derived from a Kaplan–Meier curve) was determined by a log-rank test on the intention-to-treat population. Study subjects were in reasonable metabolic control, with an average baseline HbA1c of 7.0±1.1, blood pressure of 128/76±14/9, and total and LDL cholesterol of 179±42 and 98±32, respectively, with 88%, 77%, and 69% of subjects being treated with antidiabetic, antihypertensive, and antihyperlipidemic agents, respectively. Ninety-one percent of the expected person-year outcome ascertainment was obtained in this study. Respecting the CV-inclusive composite cardiovascular end point, there were 39 events (1.9%) among 2054 bromocriptine-QR-treated subjects versus 33 events (3.2%) among 1016 placebo subjects, yielding a significant, 39% reduction in relative risk in this end point with bromocriptine-QR exposure (P=0.0346; log-rank test) that was not influenced by age, sex, race, body mass index, duration of diabetes, or preexisting cardiovascular disease. In addition, regarding the MACE end point, there were 14 events (0.7%) among 2054 bromocriptine-QR-treated subjects and 15 events (1.5%) among 1016 placebo-treated subjects, yielding a significant, 52% reduction in relative risk in this end point with bromocriptine-QR exposure (P<0.05; log-rank test). Conclusions-—These findings reaffirm and extend the original observation of relative risk reduction in cardiovascular adverse events among type 2 diabetes subjects treated with bromocriptine-QR and suggest that further investigation into this impact of bromocriptine-QR is warranted. Clinical Trial Registration-—URL: http://clinicaltrials.gov. Unique Identifier: NCT00377676 (J Am Heart Assoc. 2012;1:e002279 doi: 10.1161/ JAHA.112.002279)read more
Citations
More filters
Standards of Medical Care in Diabetes
TL;DR: These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care.
Journal ArticleDOI
Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations
TL;DR: This review considers the mechanisms, history, controversies, new pharmacological agents, and recent evidence for current guidelines for cardiovascular management in the patient with diabetes mellitus to support evidence-based care outside of the acute care setting.
Journal ArticleDOI
Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm--2016 executive summary.
Alan J. Garber,Martin J. Abrahamson,Joshua I. Barzilay,Lawrence Blonde,Zachary T. Bloomgarden,Michael A. Bush,Samuel Dagogo-Jack,Ralph A. DeFronzo,Daniel Einhorn,Vivian Fonseca,Jeffrey R. Garber,W. Timothy Garvey,George Grunberger,Yehuda Handelsman,Robert R. Henry,Irl B. Hirsch,Paul S. Jellinger,Janet B. McGill,Jeffrey I. Mechanick,Paul D. Rosenblit,Guillermo E. Umpierrez +20 more
TL;DR: This chapter discusses the development and use of eicosapentaenoic acid as a treatment for diabetic ketoacidosis and its applications in conventional and regenerative medicine.
Journal ArticleDOI
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
Alan J. Garber,Martin J. Abrahamson,Joshua I. Barzilay,Joshua I. Barzilay,Lawrence Blonde,Zachary T. Bloomgarden,Michael A. Bush,Michael A. Bush,Samuel Dagogo-Jack,Ralph A. DeFronzo,Daniel Einhorn,Vivian Fonseca,Jeffrey R. Garber,W. Timothy Garvey,George Grunberger,Yehuda Handelsman,Irl B. Hirsch,Paul S. Jellinger,Janet B. McGill,Jeffrey I. Mechanick,Jeffrey I. Mechanick,Jeffrey I. Mechanick,Paul D. Rosenblit,Guillermo E. Umpierrez,Guillermo E. Umpierrez +24 more
TL;DR: The objective of the trial was to establish whether or not the initial treatment strategy improved the patient’s quality of life and/or lowered the risk of adverse events.
Journal ArticleDOI
Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summary
Alan J. Garber,Martin J. Abrahamson,Joshua I. Barzilay,Lawrence Blonde,Zachary T. Bloomgarden,Michael A. Bush,Samuel Dagogo-Jack,Ralph A. DeFronzo,Daniel Einhorn,Vivian Fonseca,Jeffrey R. Garber,W. Timothy Garvey,George Grunberger,Yehuda Handelsman,Irl B. Hirsch,Paul S. Jellinger,Janet B. McGill,Jeffrey I. Mechanick,Paul D. Rosenblit,Guillermo E. Umpierrez +19 more
TL;DR: This monograph describes the development and use of various strategies to reduce the risk of heart attack and stroke in patients with type 2 diabetes through a variety of treatments, including vaccination, diet and lifestyle modifications.
References
More filters
Journal ArticleDOI
Diagnosis and Classification of Diabetes Mellitus
TL;DR: The chronic hyperglycemia of diabetes is associated with long-term damage, dys-function, and failure of differentorgans, especially the eyes, kidneys, nerves, heart, and blood vessels.
Standards of Medical Care in Diabetes
TL;DR: These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care.
Journal ArticleDOI
Standards of medical care in diabetes.
TL;DR: I would like to take issue with the use of the phrase “standards of medical care in diabetes,” which is used to describe diabetes care standards, in the recently updated and circulatedADA 2006 Clinical Practice Recommendations.
Journal ArticleDOI
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein,Michael Miller,Robert P. Byington,David C. Goff,J. Thomas Bigger,John B. Buse,William C. Cushman,Saul Genuth,Faramarz Ismail-Beigi,Faramarz Ismail-Beigi,Richard H. Grimm,Jeffrey L. Probstfield,Denise G. Simons-Morton,William T. Friedewald +13 more
TL;DR: In this paper, the authors investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors.
Journal ArticleDOI
Standards of Medical Care in Diabetes: Response to Power
TL;DR: The title “Standards of Medical Care in Diabetes” was chosen because in the view of the American Diabetes Association (ADA), the recommendations represent what the association considers the “standards” for the care of patients with diabetes.
Related Papers (5)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica,Deepak L. Bhatt,Deepak L. Bhatt,Eugene Braunwald,P. Gabriel Steg,Jaime A. Davidson,Boaz Hirshberg,Peter Öhman,Robert Frederich,Stephen D. Wiviott,Elaine B. Hoffman,Matthew A. Cavender,Jacob A. Udell,Nihar R. Desai,Ofri Mosenzon,Darren K. McGuire,Kausik K. Ray,Lawrence A. Leiter,Itamar Raz +18 more
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A. Dormandy,Bernard Charbonnel,David Eckland,Erland Erdmann,Massimo Massi-Benedetti,Ian K. Moules,Allan M. Skene,Meng H. Tan,P. J. Lefebvre,Gordon D Murray,Eberhard Standl,Robert G. Wilcox,Lars Wilhelmsen,John Betteridge,Kåre I. Birkeland,Alain Golay,Robert J. Heine,László Korányi,Markku Laakso,Marián Mokáň,Antanas Norkus,Valdis Pirags,Toomas Podar,André Scheen,Werner A. Scherbaum,Guntram Schernthaner,Ole Schmitz,Jan Škrha,Ulf Smith,Jan Tatoň +29 more
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel,Stephen MacMahon,John Chalmers,Bruce Neal,Laurent Billot,Mark Woodward,Mark Woodward,Michel Marre,Mark E. Cooper,Paul Glasziou,Paul Glasziou,Diederick E. Grobbee,Pavel Hamet,Stephen B. Harrap,Simon Heller,Lisheng Liu,Giuseppe Mancia,Carl Erik Mogensen,C. Y. Pan,Neil R Poulter,Anthony Rodgers,Bryan Williams,Severine Bompoint,Bastiaan E. de Galan,Bastiaan E. de Galan,Rohina Joshi,F. Travert +26 more